SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Novavax NVAX -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (34)6/11/2009 9:10:12 PM
From: Rock_nj  Read Replies (1) | Respond to of 166
 
Don't forget that Novavax might get approval overseas first in a country like India. Also, they are speeding up their Phase II/III trials in the U.S., and there is always the possibility of expedited FDA approval, which the NIH research might be a part of. This is not a story for this week or next, but by later this year NVAX could have revenues and a much higher stock price. The pandemic is just getting started.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News